Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients

Table 2 Biochemical, virological, and serological responses n (%)

	Value for patient group
	TDF(n = 28)	LAM + ADV(n = 31)	P value
Normalization of ALT1
Week 12	21 (75.00)	5 (17.86)	< 0.001
Week 24	22 (78.57)	17 (54.84)	0.097
Week 48	25 (89.26)	21 (67.74)	0.062
HBV DNA undetectability (< 103 copies/mL)
Week 4	5 (17.86)	2 (6.45)	0.240
Week 12	21 (75.00)	5 (16.13)	< 0.001
Week 24	23 (82.14)	7 (22.58)	< 0.001
Week 36	25 (89.29)	8 (25.81)	< 0.001
Week 48	27 (96.43)	9 (29.03)	< 0.001
HBeAg loss at week 48	1 (4)	0	0.481

¹The alanine aminotransferase (ALT) reference range was < 50 U/L. TDF: Tenofovir disoproxil fumarate; LAM: Lamivudine; ADV: Adefovir; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.